
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences has shown an improvement in investor confidence following the lifting of the partial clinical hold for its product candidate Zetomipzomib (KZR-616) in the treatment of autoimmune hepatitis (AIH), indicating a positive risk-benefit profile for this indication. The potential full removal of the clinical hold for lupus nephritis (LN) is expected to significantly enhance investor sentiment and could facilitate the resumption of development efforts, broadening the therapeutic applications of the drug. Overall, these developments indicate a promising trajectory for Kezar Life Sciences’s pipeline, suggesting a favorable commercial outlook as the company aims to address unmet medical needs in both autoimmunity and cancer.
Bears say
Kezar Life Sciences is currently facing significant challenges related to its clinical-stage pipeline, particularly with Zetomipzomib (KZR-616) and KZR-261, which may affect its future revenue prospects and market position in the competitive biotechnology landscape. The company's financials indicate high research and development expenditures without a corresponding increase in successful product development or partnerships, leading to concerns about financial sustainability. Additionally, the ongoing need for substantial capital to fund clinical trials may dilute shareholder value and hinder the company's ability to achieve timely product commercialization.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares